Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Industrial Biotechnology Reasearch Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
J Exp Clin Cancer Res. 2019 Apr 24;38(1):172. doi: 10.1186/s13046-019-1169-0.
Thousands of long noncoding RNAs (lncRNAs) are aberrantly expressed in various types of cancers, however our understanding of their role in the disease is still very limited.
We applied RNAseq analysis from patient-derived data with validation in independent cohort of patients. We followed these studies with gene regulation analysis as well as experimental dissection of the role of the identified lncRNA by multiple in vitro and in vivo methods.
We analyzed RNA-seq data from tumors of 456 CRC patients compared to normal samples, and identified SNHG15 as a potentially oncogenic lncRNA that encodes a snoRNA in one of its introns. The processed SNHG15 is overexpressed in CRC tumors and its expression is highly correlated with poor survival of patients. Interestingly, SNHG15 is more highly expressed in tumors with high levels of MYC expression, while MYC protein binds to two E-box motifs on SNHG15 sequence, indicating that SNHG15 transcription is directly regulated by the oncogene MYC. The depletion of SNHG15 by siRNA or CRISPR-Cas9 inhibits cell proliferation and invasion, decreases colony formation as well as the tumorigenic capacity of CRC cells, whereas its overexpression leads to opposite effects. Gene expression analysis performed upon SNHG15 inhibition showed changes in multiple relevant genes implicated in cancer progression, including MYC, NRAS, BAG3 or ERBB3. Several of these genes are functionally related to AIF, a protein that we found to specifically interact with SNHG15, suggesting that the SNHG15 acts, at least in part, by regulating the activity of AIF. Interestingly, ROS levels, which are directly regulated by AIF, show a significant reduction in SNHG15-depleted cells. Moreover, knockdown of SNHG15 increases the sensitiveness of the cells to 5-FU, while its overexpression renders them more resistant to the chemotherapeutic drug.
Altogether, these results describe an important role of SNHG15 in promoting colon cancer and mediating drug resistance, suggesting its potential as prognostic marker and target for RNA-based therapies.
数千种长非编码 RNA(lncRNA)在各种类型的癌症中异常表达,但我们对它们在疾病中的作用的理解仍然非常有限。
我们应用了来自患者衍生数据的 RNA-seq 分析,并在独立的患者队列中进行了验证。在这些研究之后,我们通过多种体外和体内方法进行了基因调控分析以及对鉴定的 lncRNA 作用的实验剖析。
我们分析了 456 例 CRC 患者肿瘤与正常样本的 RNA-seq 数据,发现 SNHG15 是一种潜在的致癌 lncRNA,其一个内含子编码 snoRNA。加工后的 SNHG15 在 CRC 肿瘤中过度表达,其表达与患者的不良预后高度相关。有趣的是,SNHG15 在 MYC 表达水平较高的肿瘤中表达更高,而 MYC 蛋白与 SNHG15 序列上的两个 E-box 基序结合,表明 SNHG15 转录受致癌基因 MYC 的直接调控。用 siRNA 或 CRISPR-Cas9 敲低 SNHG15 可抑制 CRC 细胞的增殖和侵袭,减少集落形成和致瘤能力,而其过表达则产生相反的效果。对 SNHG15 抑制后的基因表达分析显示,多个与癌症进展相关的相关基因发生变化,包括 MYC、NRAS、BAG3 或 ERBB3。这些基因中的几个与我们发现与 SNHG15 特异性相互作用的 AIF 蛋白功能相关,表明 SNHG15 至少部分通过调节 AIF 的活性起作用。有趣的是,直接受 AIF 调节的 ROS 水平在 SNHG15 耗尽的细胞中显著降低。此外,SNHG15 的敲低增加了细胞对 5-FU 的敏感性,而过表达则使它们对化疗药物更具抵抗力。
总之,这些结果描述了 SNHG15 在促进结肠癌和介导耐药性方面的重要作用,表明其作为预后标志物和基于 RNA 的治疗靶点的潜力。